Mersana Therapeutics Inc (NAS:MRSN)
$ 2.37 0.07 (3.04%) Market Cap: 292.77 Mil Enterprise Value: 160.46 Mil PE Ratio: 0 PB Ratio: 237.00 GF Score: 29/100

Mersana Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 11, 2020 / 04:00PM GMT
Release Date Price: $21.96 (+2.43%)
Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Welcome, everyone, to the Annual Crédit Suisse Healthcare Conference. We're joined today by Anna Protopapas, CEO of Mersana Therapeutics. And she's going to give us a presentation on all the recent developments for Mersana. You can take it away, Anna.

Anna Protopapas
Mersana Therapeutics, Inc. - President, CEO & Director

Thank you, Tiago, and thank you for having us today and for the opportunity to tell you more about Mersana and why we're so excited about the potential of our current clinical programs and robust pipeline of ADC candidates. Before I start, I do want to remind you that I will be making forward-looking statements.

Mersana was founded on the vision that innovative new ADC platforms that address the limitations of the first-generation approaches could lead to therapies that could significantly improve outcomes for cancer patients in need. These platforms are: proprietary DolaLock payload with controlled bystander effect; our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot